Ask AI
ProCE Banner Activity

Expert Q&A on Rapid Phenotypic AST for Bloodstream Infections

Clinical Thought

Read answers to learner questions from a symposium discussing the ongoing challenge of antimicrobial selection for bloodstream infections and the role of rapid phenotypic antimicrobial susceptibility tests in guiding treatment.

Released: December 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with ProCE

ProCE Banner

Supporters

Supported by an educational grant from bioMérieux.

bioMérieux

Partners

ProCE

ProCE Banner

Target Audience

This activity is intended for ID specialists, including physicians, pharmacists, nurse practitioners, and physician associates, and other HCPs who provide care for patients with BSIs. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the potential benefits of rapid phenotypic AST for patients with Gram-negative BSIs

  • Utilize rapid genotypic and phenotypic AST results to inform antibiotic selection for patients with Gram-negative BSIs

  • Formulate strategies for optimal integration of rapid phenotypic AST into clinical practice, including incorporation into antimicrobial stewardship workflow

Disclosure

Primary Author

Jose Alexander, MD, D(ABMM), CIC, FCCM, SM/MB(ASCP): consultant/advisor/speaker: AbbVie, BioMerieux, Cepheid, Melinta, Merck, Shionogi.

Jasmine R. Marcelin, MD, FACP, FIDSA, has no relevant financial relationships to disclose.

Michael P. Veve, PharmD, MPH: consultant/advisor/speaker: BioMerieux Inc, Merck Sharp & Dohme; researcher: Innoviva Therapeutics.